Skip to main content
Download PDF

Evaluation of serum 25-Hydroxy vitamin D levels in children with autism Spectrum disorder

Italian Journal of Pediatrics volume 44, Article number: 150 (2018) Cite this article

A Correction to this article was published on 04 February 2019

This article has been updated

Abstract

Background

Vitamin D plays an important role in etiology of Autism Spectrum Disorders (ASDs). We aimed to evaluate the serum 25 - hydroxyl vitamin D level among children with ASDs in Ahvaz city, Iran.

Methods

It was a cross-sectional study which had conducted on 62 subjects in two groups: a case group (n = 31) consisted of ASD children who study in especial schools; and a control group (n = 31) of healthy children who were selected by simple random sampling from regular schools in Ahvaz city, Iran during 2016. Maching between two groups has done regarding Socioeconomic status, type and amount of food intake, place of living and age. The levels of serum 25 - hydroxyl vitamin D were assessed in early morning means fasted state and also measured using ELISA method. Data were analyzed using Statistical Package for Social Sciences (SPSS) version 20. The significant level was considered < 0.05.

Results

In ASD children, the average serum 25-hydroxyvitamine D level was 9.03 ± 4.14 ng/mg. In ASD group, 96.8% (30 subjects) had vitamin D deficiency. In healthy children group, average serum 25-hydroxyvitamine D level was 15.25 ± 7.89 ng/mg. Average serum 25-hydroxyvitamine D level in intervention group was significantly lower than the control group (P > 0.001). Although the parents of patients in control group reported longer exposure to sun (27.42 m per day against 33.06 m per day), no significant difference was observed between these groups in terms of exposure to sun (P < 0.05).

Conclusions

A significant difference was observed between serum 25-hydroxyvitamine D levels between the healthy and ASD children. It is recommended to use vitamin D supplement in children with ASDs under medical care.

Introduction

Vitamin D may play an important role in etiology of Autism Spectrum Disorders (ASDs). Vitamin D is a neuroactive steroid affecting brain development and function. It plays an essential role in myelination, which is important for connectivity in the brain. Studies have shown that decreased vitamin D levels, decreased maternal vitamin D levels during pregnancy, and decreased exposure to solar UVB might increase the risk of ASD [1].

Despite extensive studies on ASD, the etiology of this disorder is quite unknown and studies are ongoing [2, 3]. ASD has a dominant genetic origin. However, environmental and genetic factors have interaction in the incidence of this disorder [3,4,5]. The results of studies have shown that in disease etiology, risk factors such as prenatal and postnatal infections [6, 7], and exposure to Valproic Acid of alcohol during pregnancy [8, 9], the age of mother [10], and abnormal nutritional and metabolic factors [3] are effective. During the recent years, the incidence of ADSs has been significantly increased. In previous studies, the incidence of this disorder was 10 in 10,000 [11], whereas the incidence of this disorder is now estimated as 90–250 in 10,000 [12,13,14,15]. In addition, in 2010, CDC reported the incidence of autism disorder in the United States as 1 in 68 and this indicates 78% increase in the incidence level compared with 2002 [16]. However, a part of this sudden increase is probably the result of increased awareness and better reports about autism disorder as well as improved diagnostic criteria, but the exact causes for this sudden increase should be determined in future studies [17]. Increased incidence of the disease can impose a heave financial burden on the society. It is estimated that medication costs for each patient will be 40,000 to 60,000 dollar per year [16]. During the past decades, numerous studies were conducted on the role of vitamin D in neuropsychological disorders [18,19,20,21,22,23]. The findings of these studies showed that vitamin D deficiency is one of the risk factors of evolutional neuropsychological disorders such as schizophrenia [24] and autism [19, 25,26,27,28]. However, studies on the relationship between vitamin D and autism in different parts of the world such as Sweden [29], Egypt [20], Saudi Arabia [30], and China [31, 32] indicate lower 25 (OH) D level in patients with ASD in different ages compared with the control group. Moreover, some studies [33, 34] have shown different findings and no significant difference was observed between serum levels of vitamin D in ADS and control groups. To our knowledge few studies have been conducted in this regard in Iran and no study has been conducted in Ahvaz city, Southwestern Iran. Therefore, the present study aimed to evaluate the serum 25 - hydroxyl vitamin D level among children with ASDs in Ahvaz city, Iran.

Methods

It was a cross-sectional study which had conducted on 62 children in two groups: a case group (n = 31) consisted of ASD children who study in especial schools; and a control group (n = 31) of healthy children were selected from regular schools by using simple random sampling approach in Ahvaz city, Iran; 2016.

The two groups were matched in terms of gender, age, weight, height, head circumference, adequate breastfeeding (for at least six months), type and amount of food, socioeconomic status (the ratio of the number of family members to bedrooms was used as a measure of socioeconomic status) [35, 36], average income, family size, and exposure to smokers.

Inclusion criteria

Students with ASDs entered the study by confirming the diagnosis by a neurologist and based on DSM-IV criteria and obtaining written informed consent from the parents. In the control group, the informed consent of parents was among the inclusion criteria, too.

Exclusion Criteria of the study were the presence of epilepsy and the use of vitamin D supplements were considered as exclusion criteria.

Clinical evaluation of patients with autism

Diagnosis of patients with ASD based on medical experience, clinical examination, and two criteria of DSM-IV and ADI-R was confirmed by a neurology expert.

Evaluation of serum 25-hydroxyvitamine D level

The levels of serum 25 - hydroxyl vitamin D were assessed in early morning means fasted state.

An expert nurse collected 5 mL blood of children to measure 25 (OH) D serum levels in a Blood Transfusion Center in Ahvaz city, Khuzestan, Iran. The serum samples were isolated after centrifugation and kept at − 20 °C until the laboratory assessments. The serum 25 (OH) D levels were measured using the ELISA method (Euroimmun kit, Medizinische Labordiagnostika AG, Germany, EQ. 6411–9601).

According to the guidelines of the American Endocrine Association, vitamin D level is defined with the concentration of 25-hydroxyvitamine D3 in blood. Natural, insufficient, and deficient vitamin D levels were determined with 25-hydroxyvitamine D level lower than 20 ng/ml, 21–29 ng/ml, and 30 ng/ml, respectively [36].

All the tests in this study were performed in Nargess Laboratory in Ahvaz city under the supervision of a doctor of medical laboratory sciences. Tests were performed two times and the averaged values were used in the analyses to increase the accuracy of the results.

Ethical considerations

Prior permissions from educational authorities, school principals, and class teachers were obtained, and then written informed consent form was taken from the parents’ children participate. The procedures of this study were approved by Independence Ethics Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran (IR.AJUMS.REC.1394.199) also we have thanks to all subjects and their parents to participate in this study. Parents of children had informed consent to participate in this study.

Statistical analysis

Kolmogorov-Smirnov test was performed prior to statistical analysis to examine the normality of the variables. The results were presented in the form of statistical tables and numeric indicators. Chi-square test, t-test, and nonparametric test (Mann-Whitney U test) were used to analyze the data. Variable values were expressed as frequency, mean ± standard deviation (SD). Statistical calculations were performed using Statistical Package for Social Sciences version 20 (SPSS Inc., Chicago, IL, USA). For all statistical analyses, P value less than 0.05 was considered as significant.

Results

The finding has shown that 31 children with ASD and 31 healthy children with age range of 5–12 years old. No significant difference was observed between two groups in terms of age (P = 0.80). In addition, no significant difference was observed between the mean of mother’s age at the birth of the child in both groups (P = 0.28). Most of the subjects in the case and control groups were male (83.9 and 90.3%, respectively) and no significant difference was observed in both groups in terms of gender (P = 0.45). Most of children in the case group were Bakhtiari (35.5%) and in the control group were Arab (Table 1).

Table 1 Demographic characteristics in two groups
Full size table
Table 2 Serum vitamin D level and exposure to direct sun in two groups
Full size table

In ASD children, the serum 25-hydroxy vitamin D level was significantly lower than the control group (P > 0.001). In the ASD group, all children showed deficient or insufficient level of serum 25-hydroxy vitamin D (96.8% or 3.2%, respectively).

In both groups, the use of direct daily sun was equal (67.74%). No significant difference was observed between the groups in exposure to direct sun (min/day) (P-0.56) (Table 2).

Discussion

Recently, the role of vitamin D deficiency is identified as an environmental risk factor for some of autoimmune disorders [37, 38]. A study by Patrick and colleagues showed that vitamin D ma influence some of social behaviors of children with autism. He emphasized that vitamin D is a gene activator that creates tryptophan hydroxylase enzyme. This enzyme converts tryptophan into serotonin in the brain. Therefore, a sufficient level of vitamin D to produce serotonin in the brain than functions as a neuron transmitter improves social behaviors by positive effects on behavior [39]. In a clinical trial study by Feng and colleagues on 37 children with autism, for three months, these children received 150,000 IU as intramuscular injection(monthly) and 400 IU orally (daily). These researchers reported that disease symptoms and behavioral checklist in children (3 years old and older) with autism improved [40]. In most of the studies conducted on ASDs and vitamin D, lower 25-hydroxyvitamine D level in children with autism was taken into consideration. Our findings showed low level 25-hydroxyvitamine D level in the ASD children, compared with the healthy counterparts. Testes et al. reported that the mean of serum 25-hydroxyvitamine D level in children with autism with different ethnicities was lower than the control group by 35 nmol/L [41]. Moreover, Duan et al. showed that serum 25-hydroxyvitamine D in patients with autism was significantly lower than the control group [31]. Bener et al. attributed some biological and lifestyle factors such as birth, kinship, body mass profile, and physical activity and 25-hydroxyvitamine D level with the incidence of autism. Their findings showed that serum 25-hydroxyvitamine D level in ASD children was lower than the control group with similar ethnicity, age, and gender (P = 0.004) [42]. This finding was supported by the study of Meguid et al. [20]. Saad et al. [18] reported an inverse relationship between the averaged serum 25-hydroxyvitamine D level and severity of ASD (P > 0.001), which was not evaluated in our study. In another study in Saudi Arabia on comparing serum 25-hydroxyvitamine D level and MAG among 50 children with autism (5–12 years old) and 30 healthy children, a significant negative relationship was observed between serum 25-hydroxyvitamine D level and incidence of autism (P > 0.001) [30]. Neumeyer and colleagues reported that the ration of male children with ASD with serum 25-hydroxyvitamine D level lower than 80 nmol/L was higher than healthy subjects (77% against 37% and p = 0.02). However, the results of a study by Molloy [33] and Esparham [3] in the United States showed that there is not significant relationship between serum 25-hydroxyvitamine D level in two groups of children with ASD and without ASD. Ugur and colleagues investigated vitamin D3 level of 54 children with autism and 54 healthy children between 3 and 8 years old in Turkey. They did not observe any significant difference t vitamin D3 serum level between these two groups [35]. The results of a study by Hashemzeh and colleagues in Iran showed no significant difference between vitamin D in children with autism and healthy children. Also, no significant relationship was observed between serum vitamin D level and severity of the disease symptoms [34].

Conclusion

There significant difference was observed between serum 25-hydroxyvitamine D levels in two groups of this study and different studies confirm that and also there was no significant difference between two groups in time of exposure to sun. Therefore it is recommended to use vitamin D supplement in children with ASDs under medical care.

Change history

  • 04 February 2019

    The original article [1] contained an error in author Mohammad Taghi Mansouri’s name.

References

  1. Fernell E, Bejerot S, Westerlund J, Miniscalco C, Simila H, Eyles D, Gillberg C, Humble MB. Autism spectrum disorder and low vitamin D at birth: a sibling control study. Molecular Autism. 2015;6:3.

    Article  Google Scholar 

  2. Fahmy SF, Sabri NA, El Hamamsy MH, El Sawi M, Zaki OK. Vitamin D Intake and Sun Exposure in Autistic Children. IJPSR. 2016;7(3):1043–9.

    CAS  Google Scholar 

  3. Esparham AE, Smith T, Belmont JM, Michael Haden BA, Wagner LE, Evans RG, Drisko JA. Nutritional and Metabolic Biomarkers in Autism SpectrumDisorders: An Exploratory Study. Integrative Medicine. 2015;14(2):40–53.

    PubMed  Google Scholar 

  4. Chaste P, Leboyer M. Autism risk factors: genes, environment, and gene-environment interactions. Dialogues Clin Neurosci. 2012;14:281–92.

    PubMed  PubMed Central  Google Scholar 

  5. Coleman M, Gillberg C. The autisms. Oxford: Oxford University; 2012.

    Google Scholar 

  6. Patterson PH. Maternal infection and immune involvement in autism. Trends Mol Med. 2011;17:389–94.

    Article  CAS  Google Scholar 

  7. Ohkawara T, Katsuyama T, Ida-Eto M, Narita N, Narita M. Maternal viral infection during pregnancy impairs development of fetal serotonergic neurons. Brain and Development. 2015;37:88–93.

    Article  Google Scholar 

  8. Meador KJ, Loring DW. Prenatal valproate exposure is associated with autism spectrum disorder and childhood autism. J Pediatr. 2013;163:924.

    Article  Google Scholar 

  9. Landgren M, Svensson L, Strömland K, Andersson GM. Prenatal alcohol exposure and neurodevelopmental disorders in children adopted from Eastern Europe. Pediatrics. 2010;125:e1178–85.

    Article  Google Scholar 

  10. Idring S, Magnusson C, Lundberg M, Ek M, Rai D, Svensson AC, et al. Parental age and the risk of autism spectrum disorders: findings from a Swedish population-based cohort. Int J Epidemiol. 2014;43:107–15.

    Article  Google Scholar 

  11. Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children. JAMA. 2001;285:3093–9.

    Article  CAS  Google Scholar 

  12. New Zealand Guidelines Group. What does ASD look like? In a resource to help identify autism Spectrum disorder. Wellington: New Zealand Guidelines Group; 2010.

    Google Scholar 

  13. Kogan MD, Blumberg SJ, Schieve LA, Boyle CA, Perrin JM, Ghandour RM, Singh GK, Strickland BB, Trevathan E, van Dyck PC. Prevalence of parent-reported diagnosis of autism Spectrum disorder among children in the us, 2007. Pediatrics. 2009;124:1395–403.

    Article  Google Scholar 

  14. Ghanizadeh A. A preliminary study on screening prevalence of pervasive developmental disorder in schoolchildren in Iran. J Autism Dev Disord. 2008;38:759–76.

    Article  Google Scholar 

  15. Baio J. Prevalence of Autism Spectrum Disorders—Autism and Developmental Disabilities Monitoring Network,14 Sites, United States, 2008; Morbidity and mortality weekly report; Surveillance summaries, vol. 61. Atlanta: Centers for Disease Control and Prevention; 2012. p. 1–19.

    Google Scholar 

  16. Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators; Centers for Disease Control and Prevention (CDC). Prevalence of autism spectrum disorder among children aged 8 years— autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ. 2014;63(2):1–21.

    Google Scholar 

  17. Hansen SN, Schendel DE, Parner ET. Explaining the increase in the prevalence of autism Spectrum disorders: the proportion attributable to changes in reporting practices. JAMA Pediatr. 2015;169:56–62.

    Article  Google Scholar 

  18. Saad K, Abdel-Rahman AA, Elserogy YM, Al-Atram AA, Cannell JJ, Bjørklund G, et al. Vitamin D status in autism spectrum disorders and the efficacy of vitamin D supplementation in autistic children. Nutr Neurosci. 2015;19(8):346–51.

    Article  Google Scholar 

  19. Kočovsk E, Fernell E, Billstedt E, Minnis H, Gillberg C. Vitamin D and autism: clinical review. Res Dev Disabil. 2012;33:1541–50.

    Article  Google Scholar 

  20. Meguid NA, Hashish AF, Anwar M, Sidhom G. Reduced serum levels of 25-hydroxy and 1,25-dihydroxy vitamin D in Egyptian children with autism. J Altern Complement Med. 2010;16:641–5.

    Article  Google Scholar 

  21. Bener A, Hoffmann GF. Nutritional rickets among children in a sun rich country. Int J Pediatr Endocrinol. 2010;2010:410–502.

    Article  Google Scholar 

  22. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–30.

    Article  CAS  Google Scholar 

  23. Eyles DW, Burne TH, McGrath JJ. Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front Neuroendocrinol. 2013;34:47–64.

    Article  CAS  Google Scholar 

  24. McGrath J. Is it time to trial vitamin D supplements for the prevention of schizophrenia? Acta Psychiatr Scand. 2010;121:321–4.

    Article  Google Scholar 

  25. Cannell JJ. Autism and vitamin D. Med Hypotheses. 2008;70:750–9.

    Article  CAS  Google Scholar 

  26. Bakare MO, Munir KM, Kinney DK. Association of hypomelanotic skin disorders with autism: links to possible etiologic role of vitamin-D levels in autism? Hypothesis (Tor), vol. 9; 2011. p. e2.

    Google Scholar 

  27. Cannell JJ, Grant WB. What is the role of vitamin D in autism? Dermatoendocrinol. 2013;5:199–204.

    Article  Google Scholar 

  28. Gentile I, Zappulo E, Militerni R, Pascotto A, Borgia G, Bravaccio C. Etiopathogenesis of autism spectrum disorders: fitting the pieces of the puzzle together. Med Hypotheses. 2013;81:26–35.

    Article  Google Scholar 

  29. Humble MB, Gustafsson S, Bejerot S. Low serum levels of 25-hydroxyvitamin D (25-OHD) among psychiatric out-patients in Sweden: relations with season, age, ethnic origin and psychiatric diagnosis. J Steroid Biochem Mol Biol. 2010;121(1-2):467–70.

    Article  CAS  Google Scholar 

  30. Mostafa GA, Al-Ayadhi LY. Reduced serum concentrations of 25-hydroxy vitamin D in children with autism: relation to autoimmunity. J Neuroinflammation. 2012;17:201.

    Google Scholar 

  31. Duan XY, Jia FY, Jiang HY. Relationship between vitamin D and autism spectrum disorder. Zhongguo Dang Dai Er Ke Za Zhi. 2013;15:698–702.

    CAS  PubMed  Google Scholar 

  32. Gong ZL, Luo CM, Wang L, Shen L, Wei F, Tong RJ, et al. Serum 25- hydroxyvitamin D levels in Chinese children with autism spectrum disorders. Neuroreport. 2014;25:23–7.

    Article  CAS  Google Scholar 

  33. Molloy CA, Kalkwarf HJ, Manning-Courtney P, Mills JL, Hediger ML. Plasma 25(OH)D concentration in children with autism spectrum disorder. Developmental Medicine & Child Neurology. 2010;52:969–71.

    Article  Google Scholar 

  34. Hashemzadeh M, Moharreri F, Soltanifar A. Comparative study of vitamin D levels in children with autism spectrum disorder and normal children: a case-control study. Journal of Fundamentals of Mental Health. 2015 July-Aug;17(4):197–201.

    Google Scholar 

  35. C. Ug˘ur, C.K. Gu¨rkan. Serum vitamin D and folate levels in children with autism spectrum disorders. Research in Autism Spectrum Disorders. 2014;8:1641–1647.

  36. Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry. 2012;17(3):290–314.

  37. Zhang HL, Wu J. Role of vitamin D in immune responses and autoimmune diseases, with emphasis on its role in multiple sclerosis. Neurosci Bull. 2010;26:445–54.

    Article  CAS  Google Scholar 

  38. Hamza RT, Awwad KS, Ali MK, Hamed AI. Reduced serum concentrations of 25-hydroxy vitamin D in Egyptian patients with systemic lupus erythematosus: relation to disease activity. Med Sci Monit. 2011;17:CR711–8.

    Article  CAS  Google Scholar 

  39. Patrck RP, Ames BN. Vitamin D hormone regulates serotonin synthesis.Part1: relevance for autism. FASEB J. 2014;28(6):2398–413. https://doi.org/10.1096/FJ.13-246546.

    Article  Google Scholar 

  40. Feng J, Shan L, Du L, Wang B, Li H, Wang W, Wang T, Dong H, Yue X, Xu Z, et al. Clinical improvement following vitamin D3 supplementation in autism Spectrum disorder. Nutr Neurosci. 2016;20(5):284–90.

    Article  Google Scholar 

  41. Tostes MHFDS, Polonini HC, Gattaz WF, Raposo NRB, Baptista EB. Low serum levels of 25-hydroxyvitamin D (25-OHD) in children with autism. Trends Psychiatry Psychother. 2012;34:161–3.

    Article  Google Scholar 

  42. Bener A, Khattab AO, Al-Dabbagh MM. Is high prevalence of vitamin D deficiency evidence for autism disorder? In a highly endogamous population. J Pediatr Neurosci. 2014;9:227–33.

    Article  Google Scholar 

Download references

Acknowledgments

We have thanks to all subjects and their parents to participate in this study.

Funding

This study was supported by Deputy of Research in Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Availability of data and materials

Please contact author for data request.

Author information

Authors and Affiliations

  1. Social Determinant of Health Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

    Ali Asghar Arastoo, Morteza Abdullatif Khafaie, Shabnam Yosefyshad, Maryam Abshirini, Karimimalekabadi Noshin & Maria Cheraghi

  2. Department of Public Health, Health School, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

    Ali Asghar Arastoo, Morteza Abdullatif Khafaie & Maria Cheraghi

  3. Cherraan’s college of pharmacy Dr. MGR Medical University, Chennai, India

    Hesam Khojastehkia

  4. Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

    Zahra Rahimi

  5. Department of Nutrition, School of Para Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

    Syed Ahmad Hosseini

  6. Department of Anesthesiology, Columbia University Irving Medical Center, New York, NY, 10032, USA

    Mohammad Taghi Mansouri

Authors
  1. Ali Asghar Arastoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hesam Khojastehkia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zahra Rahimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Morteza Abdullatif Khafaie
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Syed Ahmad Hosseini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mohammad Taghi Mansouri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shabnam Yosefyshad
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maryam Abshirini
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Karimimalekabadi Noshin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Maria Cheraghi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AA: Carried out the studies. HK: Participated in concept and carried out the studies. ZR: Performed the statistical analysis and help drafted the manuscript. MK: Participated in design of the study and revised the manuscript. SAH: Participated in design of the study. SMM: Participated in concept of study. SY, Co-ordinate of the study. MA: Data collection. NKM: Data collection. MC: Participated in concept and design of the study also revising it critically for important intellectual content; and final approval of the version to be published. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Maria Cheraghi.

Ethics declarations

Ethics approval and consent to participate

This study was approved by Independence Ethics Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran (IR.AJUMS.REC.1394.199).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Additional information

The original version of this article has been revised. Author Mohammad Taghi Mansouri's name was corrected.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Arastoo, A., Khojastehkia, H., Rahimi, Z. et al. Evaluation of serum 25-Hydroxy vitamin D levels in children with autism Spectrum disorder. Ital J Pediatr 44, 150 (2018). https://doi.org/10.1186/s13052-018-0587-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13052-018-0587-5

Keywords

Italian Journal of Pediatrics

ISSN: 1824-7288

Contact us